Next-generation sequencing (NGS) can simultaneously sequence millions or even billions of DNA molecules to achieve large-scale, high-throughput sequencing, which is a revolutionary advancement after Sanger sequencing. At present, NGS is mainly used in clinical driver gene sequencing, which is an important link in the precise diagnosis and treatment of tumors.
FDA has approved 7 NGS products for precision medicine. Combining with the clinical needs of solid tumor diagnosis and treatment, MEDx Translational Meidicine (Simply MEDx ) has independently developed a variety of NGS Panel products: Med1CDx (601 genes), OncoCDx (191 genes) , etc.
n Whole Exons of 191 Genes
n Targeted Therapy (Sensitive/Resistant)-89 Genes
n Chemotherapy (Toxicity/Dosage)-29 Genes
n Immunotherapy-27 Genes
n Hereditary Tumor Analysis-74 genes
n Evaluation of Immunotherapy (TMB, MSI, TNB etc.)
l More NGS Panels for Solid Tumors
n CDx, medication guidance： ovarian cancer ，breast cancer，prostate cancer and pancreatic cancer PRAP inhibitor
n Washington DC commons、NCCN guide，85 genes
n ChinaMap database，over 41000 SNPs of Chinese population
n Specific scoring algorithm, analyze LOH、TAI、LST，generate GIS score
FGFR ligand gene
FGFR downstream signal transduction gene
n CDx, medication guidance: melanoma , NSCLC, renal cell carcinoma FGFR inhibitor
n Customized probes，for CDx development
If you have any of the following needs, feel free to contact us or email us at inquiry@MEDxTMC.net . We will reply within 24 hours.
1. Customized or bulk orders of IVD/CDx products.
2. Get a quote for IVD/CDx products
3. Become our distributor
4. Get customized pharmaceutical service solutions
5.Learn more about our technology and R&D